Liu Wei, Ha Minwen, Yin Nanchang
Department of Medical Oncology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Department of Thoracic Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Oncotarget. 2017 Jun 1;8(42):73198-73207. doi: 10.18632/oncotarget.18336. eCollection 2017 Sep 22.
The aim of this study was to investigate the usefulness of a novel inflammation-based prognostic system, called COP-LMR (combination of platelet count and lymphocyte to monocyte ratio), for predicting postoperative survival of patients with non-small cell lung cancer (NSCLC). COP-LMR was calculated on the basis of the obtained data. Patients with both an elevated platelet count (PLT) (>30 × 104mm-3) and a low LMR (<3.6) were assigned a score of 2, and patients with one or none of the parameters were assigned a score of 1 or 0, respectively. A total of 1120 patients who underwent complete resection were enrolled in this study. Multivariate analysis revealed that COP-LMR is an independent prognostic factor for disease-free survival (DFS) (<0.001) and overall survival (OS) (<0.001). Kaplan-Meier analysis and the log-rank test revealed that COP-LMR stratified the patients into 3 independent groups (<0.001). In conclusion, COP-LMR is a potential prognostic biomarker in patients undergoing surgery for NSCLC.
本研究的目的是探讨一种名为COP-LMR（血小板计数与淋巴细胞与单核细胞比值的组合）的基于炎症的新型预后系统对预测非小细胞肺癌（NSCLC）患者术后生存率的有用性。COP-LMR是根据所获得的数据计算得出的。血小板计数（PLT）升高（>30×10⁴/mm³）且LMR降低（<3.6）的患者得分为2，具有其中一个参数或无参数的患者分别得分为1或0。本研究共纳入1120例行根治性切除术的患者。多因素分析显示，COP-LMR是无病生存期（DFS）（<0.001）和总生存期（OS）（<0.001）的独立预后因素。Kaplan-Meier分析和对数秩检验显示，COP-LMR将患者分为3个独立组（<0.001）。总之，COP-LMR是接受NSCLC手术患者的一种潜在预后生物标志物。
